Study #2023-1073
Randomized, controlled, open-label, phase 3, global multiCenter trial to assess the efficacy and safety of Zipalertinib plus chemotherapy versus chemotherapy alone, in patients with previously untreated, locally advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 insertion (ex20ins) mutations
MD Anderson Study Status
Enrolling
Treatment Agent
TAS6417
Description
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Study phase:
Phase III
Physician name:
Yasir Elamin
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-660-1449
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.